Mobia Medical, Inc.MOBI

The IPO glow-up hasn’t fixed the fundamentals. Mobia Medical’s March quarter shows revenues of $12.1 million, but that cash haul is dwarfed by a $17.7 million net loss and operating loss of $16.9 million. The company’s filing is blunt: since inception, it has financed operations through preferred stock, debt, Vivistim System sales, and-most recently-the net proceeds from its May 2026 IPO. Translation: the cash pile is new, but the burn is not.

What Mobia actually sells. The company describes itself as developing, marketing, and selling devices for treating medical conditions, with a warranty reserve for implanted pulse generators and leads that it began booking in 2024 based on historical replacement experience. Yet the latest 10-Q does not break out segment performance, leaving investors to wonder where the Vivistim System’s promised contribution actually sits in the numbers. The filing confirms only that the company’s warranty liability is now a line item, not a growth engine.

What the filings actually say. Mobia’s 10-Q for the quarter ended 31 March 2026 shows revenues of $12.1 million, net income attributable to parent of $-17.7 million, operating loss of $-16.9 million, assets of $73.6 million, liabilities of $61.6 million, and stockholders’ equity of $-167.7 million. Cash and cash equivalents stood at $55.7 million, while net cash used in operating activities was $-17.7 million. Research and development spend was $1.7 million, inventory net was $6.0 million, and the company shelled out just $42,000 on property, plant, and equipment. Diluted weighted average shares outstanding were 918,935, with a diluted loss per share of $-19.30. (source: MOBI SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1489993/000119312526257552/mobi-20260331.htm)

Board theatre and legal small print. The company’s amended bylaws define “public disclosure” narrowly-press releases carried by national wires or SEC filings-while explicitly opting out of Delaware’s Section 116 delivery rules. The board also reserves the right to set directors’ compensation, a clause that reads less like shareholder protection and more like a built-in perk. (source: Amended and Restated Bylaws of Mobia Medical, Inc, https://www.sec.gov/Archives/edgar/data/1489993/000162828026033685/exhibit32-closing8xk.htm)

What changed since the last public read. On 15 July 2026, Mobia filed an 8-K noting that a director previously served on the boards of Invuity, Inc. (2013-2017) and Carbylan Therapeutics, Inc. (2013-2016), a disclosure that adds governance context but no financial detail. The filing index and company facts JSON on SEC EDGAR confirm these were routine governance updates rather than material operational news. (source: MOBI SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1489993; MOBI SEC submissions JSON, https://data.sec.gov/submissions/CIK0001489993.json; MOBI SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001489993.json)

What remains unproven. Mobia’s filings do not break out Vivistim System revenues, customer counts, or geographic performance, so investors cannot judge whether the device is gaining traction or merely burning cash. The warranty reserve suggests real product usage, but the 10-Q offers no breakdown of claims, replacements, or cost trends. Until segment data appears, the revenue story is effectively a black box.